RxDoctor Payments Data

Dhansukh Patel, MD

Internal Medicine · Mount Vernon, NYNPI 1639153752

Payments from drug & device makers

$1,770in general payments, 2019–2025

Across 63 payments — averaging $28.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$520
  • Exact Sciences$266
  • Ironwood Pharmaceuticals, Inc$231
  • GSK$197
  • Bayer$130
  • Johnson & Johnson$123
  • plus $302 from 8 others

What the payments were for

  • Food & beverage$1,770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,770 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$102,245
Medicare patients
75
Services billed
1,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate89$93,617
EliquisApixaban38$42,274
JardianceEmpagliflozin25$25,034
LinzessLinaclotide24$18,619
JanumetSitagliptin Phos/Metformin Hcl17$17,227
FarxigaDapagliflozin Propanediol19$16,220
TrulicityDulaglutide14$12,806
Atrovent HfaIpratropium Bromide12$8,391
TribenzorOlmesartan/Amlodipin/Hcthiazid11$3,763
Atorvastatin Calcium325$2,709
Amlodipine Besylate343$2,621
Albuterol Sulfate HfaAlbuterol Sulfate56$2,104
Metoprolol Succinate124$2,100
Omeprazole157$1,803
Gabapentin135$1,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$74$25,03425 claims
AbbVieLinzess$60$18,61924 claims
Lilly USA, LLCTrulicity$63$12,80614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Mount Vernon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →